$9.88
0.20% today
Nasdaq, Apr 04, 08:47 pm CET
ISIN
IE000GID8VI0
Symbol
GHRS
Sector
Industry

GH Research PLC Stock price

$9.86
+0.65 7.06% 1M
+3.33 51.00% 6M
+2.86 40.86% YTD
-1.13 10.28% 1Y
-10.01 50.38% 3Y
-9.39 48.78% 5Y
-9.39 48.78% 10Y
Nasdaq, Closing price Thu, Apr 03 2025
-0.54 5.19%
ISIN
IE000GID8VI0
Symbol
GHRS
Sector
Industry

Key metrics

Market capitalization $611.60m
Enterprise Value $462.90m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
P/B ratio (TTM) P/B ratio 2.87
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-50.25m
Free Cash Flow (TTM) Free Cash Flow $-41.75m
Cash position $149.32m
EPS (TTM) EPS $-0.75
P/E forward negative
Short interest 16.60%
Show more

Is GH Research PLC a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,794 stocks worldwide.

GH Research PLC Stock Analysis

Unlock Scores for Free

Analyst Opinions

9 Analysts have issued a GH Research PLC forecast:

9x Buy
100%

Analyst Opinions

9 Analysts have issued a GH Research PLC forecast:

Buy
100%

Financial data from GH Research PLC

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
- -
-
100%
- Direct Costs 0.32 0.32
0% 0%
-
-0.32 -0.32
0% 0%
-
- Selling and Administrative Expenses 15 15
35% 35%
-
- Research and Development Expense 35 35
17% 17%
-
-50 -50
22% 22%
-
- Depreciation and Amortization 0.32 0.32
0% 0%
-
EBIT (Operating Income) EBIT -50 -50
22% 22%
-
Net Profit -39 -39
9% 9%
-

In millions USD.

Don't miss a Thing! We will send you all news about GH Research PLC directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

GH Research PLC Stock News

Neutral
GlobeNewsWire
about one month ago
Phase 2b clinical trial of GH001 in patients with treatment-resistant depression on track for completion of last patient visit in the open-label extension in Q1 2025 Phase 1 clinical trial to evaluate proprietary aerosol delivery device in healthy volunteers is ongoing in the UK Full response to the IND hold on track for submission in mid-2025 Cash, cash equivalents, other financial assets and ...
Neutral
GlobeNewsWire
about 2 months ago
DUBLIN, Feb. 05, 2025 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment in depression, today announced the pricing of its previously announced underwritten public offering in the United States of 10,000,000 ordinary shares at a public offering price of $15.00 ...
Neutral
GlobeNewsWire
about 2 months ago
DUBLIN, Feb. 03, 2025 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment in depression, today announced the commencement of an underwritten public offering in the United States of $150 million of ordinary shares. All of the ordinary shares are to be offered by ...
More GH Research PLC News

Company Profile

GH Research Plc operates as a holding company which through its subsidiaries provides biopharmaceutical products and services. It develops therapeutic products for the patients who are suffering from Treatment Resistant Depression (TRD). The firm develops novel and proprietary 5-Methoxy-N and N-Dimethyltryptamine, or 5-MeO-DMT, therapies. The company was founded by Theis Terwey, Florian Schönharting and Magnus Halle in 2018 and is headquartered in Dublin, Ireland.

Head office Ireland
CEO Villy Valcheva
Employees 50
Founded 2021
Website www.ghres.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today